At 10 a.m. today (the 20th), the State Council Information Office convened a press conference, where officials from the Ministry of Industry and Information Technology provided an overview of the industrial and informatization sector’s progress during the first half of this year. Tao Qing, Director of the Bureau of Operation Monitoring and Coordination, highlighted that China’s pharmaceutical industry witnessed a significant enhancement in innovation capabilities in the first half of the year, yielding fruitful outcomes in pioneering innovative drugs and high-end medical devices. Specifically, market approval was granted to 38 innovative drugs, with 31 being domestically manufactured, representing over 80% of the total. A cluster of “world-first” innovations received concentrated approval. Concurrently, the aggregate value of outbound technology licensing deals for innovative drugs surpassed USD 100 billion, signaling a systematic leap in the innovation quality within China’s pharmaceutical industry.